Get startedLog in
    Picture of Spago Nanomedical AB (publ) logo

    SPAGO — Spago Nanomedical AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose

    Picture of Spago Nanomedical AB (publ) logoSpago Nanomedical AB (publ)
    06/05/2026 11:01
    May 6 (Reuters) - Spago Nanomedical AB (publ) SPAGO.ST:

TUMORAD-01 STUDY MEETS PRIMARY ENDPOINT OF MAXIMUM TOLERATED DOSE

Source text: ID:nMFN4LgCgW

Further company coverage: SPAGO.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Spago Nanomedical AB (publ)

    See all news